adult-onset diabetes diabetes type 2 obesity overweight
Conditions
Interventions
Subjects will be treated with vancomycin (500 mg 3 times per day), amoxicillin
(500mg, 3 times per day) or placebo for 7 days.
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: BMI 25-35 kg/m2, insulin resistant (HOMA_IR > 2.2), caucasian, male, 35-70 years, impaired glucose tolerance (IGT: 2h plasma glucose during 75g OGTT 7.8-11.1 mmol/l) and/or impaired fasting glucose (plasma glucose >= 5.6), stable body weight for at least three months (±3 kg).
Exclusion criteria
Exclusion criteria: Known allergic reaction to vancomycin, teicoplanine, amoxicillin and other β-lactam antibiotics (penicillins and cefalosporins) or related antibiotics. Diabetes mellitus, hearing disorders, cardiovascular disease, kidney disease, cancer, asthma or bronchitis, liver malfunction, major illness with a life expectancy 3 hours per week. The use of the following drugs: β-blockers, lipid lowering-drugs (e.g. PPAR γ or PPARa (fibrates) agonists), glucose-lowering agents (including all sulfonylureas, biguanides, a-glucosidase inhibitors, thiazolidinediones, repaglinide, nateglinide and insulin), anti-oxidants or chronic corticosteroids treatment (> 7 consecutive days of treatment).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Before and after treatment, insulin sensitivity (2 step hyperinsulinemic euglycemic clamp) will be investigated (hepatic and peripheral) | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary parameters are: fasting and postprandial energy expenditure and substrate metabolism (indirect calorimetry), in vivo fatty acid handling and fatty acid partitioning in skeletal muscle, and gut permeability (multi-sugar test). Furthermore, adipose tissue and skeletal muscle gene/protein expression of markers of oxidative capacity and inflammation will be determined (i.e. AMPK) in addition to inflammatory markers in plasma. Faecal and circulating short- chain fatty acids, and faecal gut microbiota composition (HITChip /NTG sequencing) will be assessed. | — |
Countries
Netherlands
Outcome results
None listed